{"prompt": "['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'General information', 'Sponsor Representative', 'Fabio Macchi, M.Sc. Manager', 'Contact', 'Head of Scientific & Clinical Portfolio Development', 'Helsinn Integrative Care', 'Helsinn Healthcare SA', 'Via Pian Scairolo, 9', '6912 Lugano-Pazzallo, Switzerland', 'Phone: +41 (0)91 - 985 21 06', 'Fax : +41 (0)91 - 985 21 94', 'e-mail: fabio.macchi@helsinn.com', 'Clinical CRO', 'Latis S.r.l.', 'Viale Sauli, 39/5', '16121 Genova - Italy', 'Phone: +39 010 562234', 'Fax: +39 010 540699', 'e-mail: info@latiscro.it', 'Contacts for safety reporting', 'CRO Contact for Serious', 'Laura Michellini', 'Adverse Events (SAEs)', 'Phone:+39010 562234', 'Fax: +39 010 540699', 'Mobile: 39 347 4785898', 'e-mail: michellini@latiscro.it', 'e-mail: info@latiscro.it', 'Sponsor Drug Safety Officer', 'Koprivec Diana, MD, Ph.D.', 'Helsinn Healthcare SA', 'P.O. Box 357', '6915 Pambio-Noranco, Switzerland', 'Phone: +41 (0) 91 9851957', 'Fax: +41 (0) 91 9852171', 'e-mail: iana.koprivec@helsinn.com', 'Copies to: drug-safety@helsinn.com', 'CONFIDENTIAL', 'Page 4 of 53']['CIP HD01-16-30', 'HHELSINN', 'Version 1.0, 06/02/2017', 'Table of contents', '1.', 'Synopsis of the Clinical Investigation Plan', 'pag.7', '2.', 'Identification and description of the investigational device', 'pag.13', '3.', 'Justification for the design of the clinical investigation', 'pag.13', '4.', 'Risk and benefits of the investigational device and clinical investigation', 'pag.15', '5.', 'Objectives and hypotheses of the clinical investigation', 'pag.16', '5.1 Primary Objective', 'pag.16', '5.2 Secondary Objectives', 'pag.16', '5.3 Tolerability and safety objectives', 'pag.16', '6.', 'Design of the clinical investigation', 'pag.16', '6.1 General', 'pag.16', '6.2 Investigational device and comparator', 'pag.17', '6.2.1 Xonrid\u00ae', 'pag.17', '6.2.1.1 Packaging and labelling', 'pag.19', '6.2.1.2 Study device instructions for use', 'pag.19', '6.2.1.3 Handling and storage', 'pag.20', '6.2.1.4 Study product accountability and compliance', 'pag.20', '6.2.2 Standard of Care (SOC)', 'pag.21', '6.2.3 Concomitant medications', 'pag.21', '6.3 Subjects', 'pag.22', '6.3.1', 'Inclusion criteria', 'pag.22', '6.3.2', 'Exclusion criteria', 'pag.22', '6.4', 'Procedures', 'pag.23', '6.4.1', 'Study visits and assessments', 'pag.23', '6.4.2', 'Erythema assessment', 'pag.25', '6.4.3', 'Spettrophotometry examination and TEWL examination', 'pag.25', '6.4.4', 'Skindex-16 questionnaire', 'pag.26', '6.4.5', 'Patient Global Satisfaction', 'pag.26', '6.5', 'Monitoring plan', 'pag.26', '7', 'Statistical considerations', 'pag.27', '7.1 Sample Size Determination', 'pag.27', '7.2 Definition of Study Populations for Analysis', 'pag.28', '7.3 Statistical Analysis', 'pag.28', '7.3.1 Missing Data', 'pag.28', '7.3.2 Multiplicity', 'pag.28', '7.3.3 Covariates, Interactions and Subgroups', 'pag.29', '7.3.4 Analysis of Demographics and Baseline Variables', 'pag.29', 'CONFIDENTIAL', 'Page 5 of 53']\n\n###\n\n", "completion": "END"}